Caliway's CBL-514 Combination Therapy Selected for Presentation at ADA 2026 Scientific Sessions

Preclinical data on CBL-514 with GLP-1R therapies to be showcased by renowned obesity expert Dr. W. Timothy Garvey

Apr. 2, 2026 at 4:51am

Got story updates? Submit your updates here. ›

Caliway Biopharmaceuticals announced that its latest preclinical research on CBL-514, a first-in-class fat reduction drug candidate, in combination with GLP-1R-based weight-loss therapies has been selected for presentation at the 2026 American Diabetes Association (ADA) Scientific Sessions, one of the world's largest and most influential meetings in diabetes and obesity.

Why it matters

The selection of Caliway's research for presentation at the prestigious ADA Scientific Sessions reflects strong recognition from global experts in metabolism for the potential of CBL-514 in combination with GLP-1R therapies to address unmet needs in obesity and metabolic diseases. This opportunity will also allow Caliway to engage with international pharmaceutical companies to further expand its global development strategy.

The details

The presentation will be delivered by Dr. W. Timothy Garvey, a globally recognized authority in obesity and metabolic medicine who serves as a scientific advisor to Caliway. The title of the selected abstract is "Combination of Tirzepatide with CBL-514 an Adipocyte-Apoptosis Agent Improves Weight Loss Durability and Adipose Tissue Remodeling in Diet-Induced Obese Rats." The ADA's Standards of Care are widely regarded as a global clinical standard, and the ADA Scientific Sessions is one of the world's largest meetings in diabetes, obesity, and metabolism.

  • The ADA's 2026 Scientific Sessions will be held from June 5 to June 8, 2026 in New Orleans, Louisiana.
  • Caliway's research has also been selected for presentation at the European Congress on Obesity (ECO) and the ADA's two premier scientific meetings in obesity and metabolism in Europe and the United States.

The players

Caliway Biopharmaceuticals

A clinical-stage biopharmaceutical company advancing innovative small-molecule therapies in aesthetic medicine, metabolic diseases, and other unmet medical needs.

W. Timothy Garvey, MD

A globally recognized authority in obesity and metabolic medicine and a scientific advisor to Caliway. He is Professor of Endocrinology and Obesity Medicine at the University of Alabama at Birmingham (UAB) and has made important contributions to multiple U.S. clinical guidelines related to obesity and metabolism.

American Diabetes Association (ADA)

An internationally authoritative non-profit medical organization whose annual Standards of Care in Diabetes are widely regarded as a global clinical standard. The ADA Scientific Sessions is one of the world's largest and most influential scientific meetings in diabetes, obesity, and metabolism.

Got photos? Submit your photos here. ›

What they’re saying

“The selection of Caliway's research on CBL-514 in combination with GLP-1R-based weight-loss therapies for presentation at one of the world's largest medical meetings in obesity and diabetes, with a globally influential KOL such as Dr. Garvey serving as the presenter, reflects continued recognition of the Company's research direction in obesity and metabolism by the global professional community.”

— Vivian Ling, CEO of Caliway

What’s next

In addition to presenting the latest scientific progress at the ADA Scientific Sessions, Caliway will also actively take this opportunity to meet face-to-face with global experts in obesity and metabolism, as well as multinational pharmaceutical companies, to further expand and deepen the global development strategy and collaboration opportunities for CBL-514.

The takeaway

Caliway's selection to present its research on the combination of CBL-514 and GLP-1R therapies at the prestigious ADA Scientific Sessions underscores the potential of this approach to address unmet needs in obesity and metabolic diseases. This recognition from global experts in the field could open up new collaboration and expansion opportunities for Caliway as it looks to advance its innovative pipeline.